ArticleInflammopharmacology2026
HPLC-characterized phenolics from Acer oblongifolium attenuate inflammation, pain, and CNS-related disturbances: docking, edema, nociception, and behavioural studies.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhenolic compounds of plant origin are promising alternatives, but the potential of Acer oblongifolium and its components has not been studied.
objectiveTo evaluate analgesic, anti-inflammatory and anxiolytic effects of Acer oblongifolium extract and four of its major phenolics, catechin, syringic acid, vanillic acid and gentisic acid-with the help of in silico, in vivo and biochemical techniques.
methodsHPLC was performed to investigate the phenolic content of the plant extract. The binding of known compounds with TNF α, IL-6 and IL-1β was evaluated with the help of molecular docking. In-vivo tests, including the hole board test, open field test, hot plate test, writhing assay, carrageenan induced paw edema and histamine induced edema were used to evaluate the pharmaceutical potential. ELISA was performed to measure serum and tissue IL-6, IL-1β and TNF-α levels.
resultsHPLC validated the presence of four phenolic compounds, including Gentisic acid, vanillic acid, catechin and syringic acid. Gentisic acid exhibited strong hydrogen binding with TNF-α and IL-1β. The most pronounced anxiolytic-like activity was exhibited by vanillic acid which decreased immobility by 60% and freezing behavior by 62% in open field test, and enhanced the latency of hot plate by 30%. Gentisic acid prevented carrageenan induced paw swelling by 82% at 3 h and vanillic acid prevented histamine induced edema by 80%, which was better than cetirizine. ELISA indicated that both Gentisic acid and catechin were the most effective in reducing high levels of IL-1β and TNF-α levels in serum and brain tissue from 4.55 to 2.035 pg/mL.
conclusionAcer oblongifolium and its phenolic constituents, principally Gentisic acid and vanillic acid, showed analgesic, anti-inflammatory, and anxiolytic-like activity in this preclinical model, potentially mediated via modulation of pro-inflammatory cytokines.
Indexed as
Identifiers
42734841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.